Skip to Content
Merck
  • Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.

Science immunology (2017-08-08)
Sarah F Andrews, M Gordon Joyce, Michael J Chambers, Rebecca A Gillespie, Masaru Kanekiyo, Kwanyee Leung, Eun Sung Yang, Yaroslav Tsybovsky, Adam K Wheatley, Michelle C Crank, Jeffrey C Boyington, Madhu S Prabhakaran, Sandeep R Narpala, Xuejun Chen, Robert T Bailer, Grace Chen, Emily Coates, Peter D Kwong, Richard A Koup, John R Mascola, Barney S Graham, Julie E Ledgerwood, Adrian B McDermott
ABSTRACT

Antigenic drift and shift of influenza strains underscore the need for broadly protective influenza vaccines. One strategy is to design immunogens that elicit B cell responses against conserved epitopes on the hemagglutinin (HA) stem. To better understand the elicitation of HA stem-targeted B cells to group 1 and group 2 influenza subtypes, we compared the memory B cell response to group 2 H7N9 and group 1 H5N1 vaccines in humans. Upon H7N9 vaccination, almost half of the HA stem-specific response recognized the group 1 and group 2 subtypes, whereas the response to H5N1 was largely group 1-specific. Immunoglobulin repertoire analysis of HA-specific B cells indicated that the H7N9 and H5N1 vaccines induced genetically similar cross-group HA stem-binding B cells, albeit at a much higher frequency upon H7N9 vaccination. These data suggest that a group 2-based stem immunogen could prove more effective than a group 1 immunogen at eliciting broad cross-group protection in humans.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated, clone A1, Chemicon®, from mouse